Protalea Bio

Protalea Bio is a biotech company developing first-in-class therapeutic antibodies to prevent progression from precancerous states to active blood cancers including multiple myeloma and B-cell lymphoma.

The company's approach targets glycosphingolipid-related inflammation before disease onset, building on over fifteen years of research into lysosomal storage disorders and the discovery of a causal link between Gaucher disease, lymphoid cancers and neuroinflammation.